Evidence mapPaperPMID 38980708Full record

ReviewBioscience reports2024

KRIT1 in vascular biology and beyond.

Angela J Glading

Abstract readReview
In one paragraph

Review in Bioscience reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Angela J GladingDepartment of Pharmacology and Physiology, University of Rochester, Rochester, NY, U.S.A.ORCID 0000-0002-1830-6601

Funding

Conformation-dependent regulation of KRIT1 and the CCM complexR01HL141131 · NHLBI · UNIVERSITY OF ROCHESTER · PI Angela J Glading · 2022 to 2022
$385k
National Heart, Lung, and Blood Institute (NHLBI) HL141131NHLBI NIH HHS R01 HL141131
6 · The paper itself

Abstract

KRIT1 is a 75 kDa scaffolding protein which regulates endothelial cell phenotype by limiting the response to inflammatory stimuli and maintaining a quiescent and stable endothelial barrier. Loss-of-function mutations in KRIT1 lead to the development of cerebral cavernous malformations (CCM), a disease marked by the formation of abnormal blood vessels which exhibit a loss of barrier function, increased endothelial proliferation, and altered gene expression. While many advances have been made in our understanding of how KRIT1, and the functionally related proteins CCM2 and PDCD10, contribute to the regulation of blood vessels and the vascular barrier, some important open questions remain. In addition, KRIT1 is widely expressed and KRIT1 and the other CCM proteins have been shown to play important roles in non-endothelial cell types and tissues, which may or may not be related to their role as pathogenic originators of CCM. In this review, we discuss some of the unsettled questions regarding the role of KRIT1 in vascular physiology and discuss recent advances that suggest this ubiquitously expressed protein may have a role beyond the endothelial cell.

Indexed as

Endothelial CellsHemangioma, Cavernous, Central Nervous SystemKRIT1 ProteinAnimalsApoptosis Regulatory ProteinsHumansMutationApoptosis Regulatory ProteinsKRIT1 ProteinKRIT1 protein, humanCCMKRIT1tumor suppressorvascular malformations

Identifiers

PMID38980708
PMCPMC11263069

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.